Last reviewed · How we verify
Gelofusine balanced
Gelofusine balanced is a colloid plasma volume expander that restores and maintains circulating blood volume in hypovolemic patients.
Gelofusine balanced is a colloid plasma volume expander that restores and maintains circulating blood volume in hypovolemic patients. Used for Acute hypovolemia and blood loss requiring volume replacement during surgery or trauma, Hypovolemic shock management.
At a glance
| Generic name | Gelofusine balanced |
|---|---|
| Sponsor | B. Braun Melsungen AG |
| Drug class | Colloid plasma volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Anesthesia |
| Phase | Phase 3 |
Mechanism of action
Gelofusine balanced is a modified fluid gelatin (succinylated gelatin) solution designed to expand intravascular volume and maintain hemodynamic stability. It functions as a colloid, remaining in the vascular space longer than crystalloid solutions, and is formulated with a balanced electrolyte composition to minimize hyperchloremic acidosis. It is used as a blood substitute or plasma expander in acute blood loss and hypovolemic shock situations.
Approved indications
- Acute hypovolemia and blood loss requiring volume replacement during surgery or trauma
- Hypovolemic shock management
Common side effects
- Allergic reactions / anaphylaxis
- Hyperamylasemia
- Coagulopathy / bleeding complications
- Acute kidney injury
- Hyperkalemia
Key clinical trials
- Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance. (PHASE2, PHASE3)
- Gelaspan vs Crystalloid Therapy in Sepsis (PHASE4)
- Gelatin in ICU and Sepsis (PHASE4)
- Biomarker-guided Intervention to Prevent Acute Kidney Injury (NA)
- A Single Group Study to Evaluate the Effects of a Boric Acid Suppository on Vaginal Health. (NA)
- Impact of Balanced Crystalloid and Colloid Infusion on Haemostasis in Healthy Male Volunteers (NA)
- 5HT2CR Balance in Brain Connectivity in Cocaine Dependence (PHASE1, PHASE2)
- The DEB Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gelofusine balanced CI brief — competitive landscape report
- Gelofusine balanced updates RSS · CI watch RSS
- B. Braun Melsungen AG portfolio CI